drugset / Trial / NCT01692197
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed. The safety of the drug combination will also be studied.
Timeline
- Start
- 2013-02-01
- Primary completion
- 2017-06-07
- Completion
- 2017-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 10 mg | Intravenous |
| Subject | Idarubicin | Small molecule | 8 mg/m2 | Intravenous |
| Subject | indisulam | Small molecule | 400 mg/m2 | Intravenous |